Unique Roles of Phosphorus in Endochondral Bone Formation and Osteocyte Maturation by Zhang, Rong et al.
Unique Roles of Phosphorus in Endochondral Bone
Formation and Osteocyte Maturation
Rong Zhang,
1,2 Yongbo Lu,
2 Ling Ye,
3 Baozhi Yuan,
4 Shibin Yu,
2 Chunlin Qin,
2 Yixia Xie,
2 Tian Gao,
2
Marc K Drezner,
4 Lynda F Bonewald,
3 and Jian Q Feng
2
1Department of Operative Dentistry and Endodontics, School of Stomatology, Fourth Military Medical University, Xi’an, People’s
Republic of China
2Biomedical Sciences, Baylor College of Dentistry, Texas A&M Health Science Center, Dallas, TX, USA
3Oral Biology, University of Missouri–Kansas City, Kansas City, MO, USA
4Department of Medicine, University of Wisconsin and GRECC, VA Medical Center, Madison, WI, USA
ABSTRACT
The mechanisms by which inorganic phosphate (Pi) homeostasis controls bone biology are poorly understood. Here we used Dmp1 null
mice, a hypophosphatemic rickets/osteomalacia model, combined with a metatarsal organ culture and an application of neutralizing
fibroblast growth factor 23 (FGF-23) antibodies to gain insight into the roles of Pi in bone biology. We showed (1) that abnormal bone
remodeling in Dmp1 null mice is due to reduced osteoclast number, which is secondary to a reduced ratio of RANKL/OPG expressed by
osteoclast supporting cells and (2) that osteoblast extracellular matrix mineralization, growth plate maturation, secondary ossification
center formation, and osteoblast differentiation are phosphate-dependent. Finally, a working hypothesis is proposed to explain how
phosphate and DMP1 control osteocyte maturation.  2011 American Society for Bone and Mineral Research.
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Introduction
R
ecently, we and other groups have demonstrated that
mutations in DMP1 result in autosomal recessive hypopho-
sphatemic rickets (ARHR) in humans. This is characterized by
rickets and the presence of large amounts of osteoid in bone
(osteomalacia) and is accompanied by elevated circulating
fibroblast growth factor (FGF-23).
(1–4) Osteocytes in Dmp1 null
mice, the model used for human ARHR, regardless of whether
they are newly formed or deeply embedded, continue to express
many molecular markers of osteoblasts and osteoid osteocytes,
such as alkaline phosphatase, type 1 collagen, and E11/gp38.
(1)
They also express elevated levels of FGF-23.
(1) These observa-
tions suggest that DMP1, a protein highly expressed in
osteocytes, might regulate the maturation of osteoid osteocytes
directly or indirectly through FGF-23 regulation of phosphate
homeostasis.
(5)
Osteocytes, which are terminally differentiated osteoblasts,
reside within the mineralized bone matrix and make up more
than 90% to 95% of all bone cells in the adult skeleton. The
differentiation of osteoblasts into osteocytes has been classified
into several stages based on cell morphology and relative
position in bone. These stages include osteoblasts residing on
the bone surface, osteoblastic osteocytes or preosteocytes,
osteoid osteocytes, and mature osteocytes embedded in a
mineralized matrix.
(6,7) As osteoblasts differentiate into mature
osteocytes, they gradually reduce their cytoplasmic volume,
protein synthesis, and secretion.
(6) However, the molecular and
cellular mechanism(s) governing this osteoblast differentiation
process are largely unknown.
Classically, phosphate homeostasis has been viewed as being
controlled by parathyroid hormone/1,25-dihydroxyvitamin D
regulation of phosphate absorption in the intestine and
reabsorption in the kidney.
(8) However, recent findings suggest
that FGF-23 is a potent phosphaturic hormone expressed
predominantly by osteocytes in bone
(1,9–10) that targets the
kidney to promote renal excretion of phosphate.
(11,12) These
observations imply that bone functions as an endocrine organ,
forming the bone-kidney axis in maintaining phosphate home-
ostasis.
(1,13) In addition to DMP1, PHEX (a phosphate-regulating
gene with homologies to endopeptidases on the X chromo-
some) also regulates FGF-23 expression in bone.
(14) PHEX is
expressed predominantly in osteoblasts and osteocytes.
(15) PHEX
mutations in mice and humans result in autosomal dominant
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1047hypophosphatemic rickets, accompanied by elevated circulating
FGF-23, a phenotype identical to that of Dmp1 null mice.
(1,9)
These observations suggest that elevated circulating FGF-23
levels and hypophosphatemia are the pathogenic factors
involved in both Phex and Dmp1 mutant mice and that presence
of hypophosphatemia and FGF-23 may inhibit osteoblast to
osteocyte differentiation. Note that FGF-23 also plays a role in
skeletal mineralization and chondrocyte differentiation that is
independent of phosphate homeostasis.
(16)
Based on observations that Dmp1 null mice show osteoma-
lacia accompanied by hypophosphatemia and elevated FGF-23
levels, this study set out to further characterize the skeletal
abnormalities in Dmp1 null mice and determine the mechanisms
responsible for those defects. We first determined whether
Dmp1 null mice show abnormalities in bone remodeling and
osteoclast function. Next, mechanistic experiments were
performed to determine whether restoration of phosphate or
blocking the activity of serum FGF-23 can rescue the skeletal
abnormalities in the Dmp1 null mice. These studies have
highlighted key roles for FGF-23 and phosphate in mediating the
DMP1 phenotype.
Materials and Methods
Mice
Dmp1 knockout (KO) mice with targeted deletion of exon 6 have
been described previously.
(17) The mice in CD-1 background
were fed with autoclaved Purina rodent chow (5010; Ralston
Purina, St. Louis, MO, USA) containing calcium, 0.67% phos-
phorus, and 4.4 IU of vitamin D per gram. The age-matched wild-
type or heterozygous mice were used as control because there is
no an apparent difference between the wild-type and the
heterozygous mice.
(1,18) All animal protocols were approved by
the Institutional Animal Care and Use Committee.
Injections of anti-FGF-23 neutralizing antibodies
Peritoneal injections of monoclonal FGF-23 antibodies [FN1 for
against the N-terminal and FC1 for against the C-terminal
fragments (see Yamazaki and colleagues for details
(19,20)) or PBS
into Dmp1 KO or the age-matched control mice (4 to 6 mice/
group) started 6 days after birth every other day at dosages
between 25 and 40mg per pup based on the age. Mice were
euthanized on days 15 and 28.
Metatarsal organ culture
Metatarsal organ cultures were performed to investigate the
effects of phosphate on the development of secondary
ossification centers. Briefly, the three central metatarsal bone
rudimentsweredissectedoutfromhindlimbsof8-day-oldDmp1
null mice and the age-matched control mice. They were cultured
in a 24-well plate, one bone per well, in 1mL of a-modified
minimum essential medium (a-MEM; Gibco BRL, Carlsbad, CA,
USA) supplemented with 0.5% fetal calf serum (FCS), 0.05mg/mL
of ascorbic acid, 0.05mg/mL of gentamicin, 100 units/mL of
penicillin, 50mg/mL of streptomycin, and various concentrations
of b-glycerophosphate. The explants were cultured for 8 days
with the medium changed every other day.
Calvarial cell culture
Calvarial cells, enriched for cells with an osteoblast phenotype,
were isolated from Dmp1 null pups and age-matched control
pups at the age of 5 days using procedures described by Feng
and colleagues.
(21) Briefly, first-passage cells were plated at a
density of 1.5 10
4cells/well in 24-well tissue culture dishes
(Costar, Corning, NY, USA). Cells were grown to confluence in a-
MEM supplemented with 7% FCS. The medium then was
changed to a-MEM supplemented with 7% FCS, 100mg/mL of of
ascorbic acid (Sigma, St Louis, MO, USA), and 5mM of b-
glycerophosphate (Sigma). This was defined as day 0. Subse-
quently,themediumwaschangedevery2daysuntilcellcultures
were stopped at day 14 and stained using the alizarin red
procedure.
Osteoclast culture and pit-formation assay
Osteoclasts were generated by coculturing splenocytes from
6-week-old mice with either 1,25-dihydroxyvitamin D3
[1,25(OH)2D3] or in the presence of recombinant macrophage
colony-stimulating factor (M-CSF) and receptor activator of NF-
kB ligand (RANKL) supplements as described previously.
(22,23)
The highly enriched bone marrow mesenchymal cells also were
used for RNA preparations for Rankl and Opg. In the experiments
using the coculture assay, individual pairs of a Dmp1 KO and
control mice were used to initiate two separate in vitro cultures
in 48-well plates and to compare the osteoclast differentiation
and bone resorption between the cells derived from KO and
control mice in a CD-1 background. The experiment was
repeated four times. The M-CSF/RANKL supplement was used to
induce osteoclast formation on tissue culture slides with 2-cm
2
chambers containing 1 10
5 splenic cells. All cultures were
initiated in medium containing DMEM supplemented with 10%
FCS, 20ng/mL of human M-CSF (R&D Biosystems, Minneapolis,
MN, USA), and 50ng/mL of RANKLþ50mg/mL of ascorba-
teþ100nM dexamethasone. The cultures were processed for
analysis on day 6. In addition, in the latter case, for each
genotype, one plate was used to perform tartrate-resistant acid
phosphatase (TRAP) staining to estimate the number of TRAP
þ
osteoclasts. With our protocol, TRAP
þ cells accounted for
approximately 95% of the total number of cells in both the
wild-type and KO cultures.
In vitro bone-resorption assay
The experimental procedure is very similar to that for the in vitro
culture of theosteoclast experiments described earlier except for
the addition of one dentin slice in each culture.
(23) After 9 days of
coculture, one set of slices was processed for TRAP staining.
Another set of the slices was incubated for an additional 3 days
and then fixed and stained with toluidine blue for photographs
of excavated pits. The experiment was repeated three times.
RT-PCR and real-time PCR
To determine the ratio of RANKL/OPG expressed by the
osteoclast precursor supporting cells in Dmp1 KO mice, total
RNA was isolated from the midshaft of Dmp1 control and KO
femurs (4 for each) using the RNeasy Mini Kit (Qiagen, Inc.,
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SuperScript III First-Strand Synthesis SuperMix for quantitative
reverse-transcriptase polymerase chain reaction (qRT-PCR;
Invitrogen, Inc., Carlsbad, CA, USA). Real-time PCR was carried
out with the Light Cycler 480 Real-Time PCR System (Roche
Molecular Biochemicals, Mannheim, Germany) using SybrGreen
PCR Master Mix (Applied Biosystems, Foster City, CA, USA) with
an initial denaturation at 958C for 10minutes, followed by 45
cycles at 958C for 30seconds, 608C for 1 minute, and 728C for
30seconds. The PCR product accumulation was monitored by
the increase in fluorescence intensity caused by binding of
SybrGreen to double-stranded DNA. The primer sequences used
areRANKL, forward: 5’-GAA ACT CACAGC CCT CTC TCT TG-3’, and
reverse: 5’-GCA TCG GAA TAC CTC TCC CAA TC-3’; OPG, forward:
5’-TAC CTG GAG ATC GAA TTC TGC TT-3’, and reverse: 5’-CCA TCT
GGA CAT TTT TTG CAA A-3’), GAPDH, forward: 5’- ACC ACA GTC
CAT GCC ATC AC -3’, and reverse: 5’- TCC ACC ACC CTG TTG CTG
TA-3’.
Fluorochrome labeling of the mineralization front
To visualize bone mineralization in mice, double fluorescence
labeling was performed as described previously.
(24) Briefly, mice
were first intraperitoneally injected with calcein green (5mg/kg),
followed by injection of an alizarin red label (5mg/kg i.p.; Sigma-
Aldrich) 5 days later. Mice were euthanized 48hours after
injection of the second label, and the bones were removed and
fixed in 70% ethanol for 48hours. The specimens were
dehydrated through a graded series of ethanol (70% to 100%)
and embedded in methyl methacrylate without prior decalci-
fication. Then 15-mm sections were cut using a Leitz 1600 saw
microtome (Ernst Leitz Wetzlar GmbH, Wetzlar, Germany). The
unstained sections were viewed under epifluorescent illumina-
tionusingaNikon(Melville,NY,USA)E800microscopeinterfaced
with the Osteomeasure histomorphometry software (Version 4.1,
Atlanta, GA, USA).
Radiography, micro–computed tomography (mCT), and
backscattered scanning electron microscope (SEM)
The long bones or vertebrae were dissected and X-rayed using a
Faxitron MX-20 (Faxitron X-Ray, Lincolnshire, IL, USA) with digital
image-capture capabilities. The long bones, vertebrae, and
metatarsals were scanned in a mCT imaging system (mCT35;
Scanco Medical, Bassersdorf, Switzerland). The nondecalcified
tibias were scanned by a FEI/Philips XL30 field-emission
environmental SEM (Hillsboro, OR, USA) using a method
described previously.
(18)
Histology
For paraffin block preparations, specimens were fixed in freshly
prepared 4% paraformaldehyde in PBS (pH 7.4), decalcified, and
embedded in paraffin by standard histologic procedures, as
described previously.
(25) Then 5-mm sections were cut and dried.
Sections were used for safranin-O staining, immunohistochem-
istry, toluidine blue staining (Sigma-Aldrich), TRAP staining, and
in situ hybridization using digoxigenin-labeled antisense RNA
(cRNA) probes, as described previously.
(1) For immunohisto-
chemistry, the following antibodies were used: DMP1 polyclonal
antibody,
(26) E11,
(27) sclerostin polyclonal antibody (R&D Biosys-
tems),andosterixmonoclonalantibody(Abcam,Cambridge,MA,
USA). For undecalcified bones, specimens were embedded in
methyl methycrylate and cut at 6-mm thickness using a Leica
2165 rotary microtome (Ernst Leitz Wetzlar). Undecalcified
sections were stained by von Kossa staining,
(17) Goldner’s
masson trichrome staining,
(1) alizarin red/alcian blue staining,
(17)
and alkaline phosphatase (ALP) cytochemistry.
(28)
Serum biochemistry
Serum calcium, phosphorus, and FGF-23 levels were determined
as described previously.
(1) Briefly, serum calcium concentration
was analyzed using a colorimetric calcium kit (Stanbio
Laboratory, Boerne, TX, USA). Serum phosphorus was measured
by the phosphomolybdate/ascorbic acid method. Serum FGF-23
level was determined by a full-length FGF-23 ELISA kit (Kainos
Laboratories, Tokyo, Japan). Data were analyzed using one-way
ANOVA with Bonferroni correction.
Statistical analysis
Data analysis was performed with the Student’s t test for two-
group comparison and with one-way ANOVA for multiple-group
comparison. If significant differences were found with one-way
ANOVA, the Bonferroni method was used to determine which
groups were significantly different from others. The quantified
results are represented as the  SEM. p<.05 was considered
statistically significant.
Results
Abnormal bone remodeling in Dmp1 null mice is
accompanied by altered osteoblast function and reduced
osteoclast formation and function
Although Dmp1 null (Dmp1 KO) newborns display no apparent
skeletal abnormalities,
(17) differences in both cartilage and bone
become evident on day 3, as reflected by comparison of alizarin
red/alcian blue–stained forelimbs (Fig. 1A). There is also a greater
accumulation of trabecular bone in the bone marrow space as
well as expanded metaphyses (Fig. 1B, left panel). This is further
supported by increased alkaline phosphatase enzyme activity
and the expanded von Kossa staining (Fig. 1B, middle and right
panels) and abnormal morphology on day 17 (Fig. 1C, left panel).
Our previous data
(1) suggest that there may be a delay in
osteoblast to osteocyte transition in Dmp1 KO mice, which
potentially would explain the increase in alkaline phosphatase
activity. In the aged animal at 1 year, the development of large
bonyprotuberancesoccursinallbonesexamined(Fig.1C,middle
and right panels, D and Supplemental Fig. S1), suggesting that
the abnormality of bone remodeling progresses with age.
To understand the mechanisms underlying the abnormal
bone remodeling, we examined osteoclast formation and
function in Dmp1 KO mice. The number of TRAP
þ (a marker
of osteoclast enzymes) cells was sharply reduced in Dmp1 KO
long bone in both the epiphyses and the metaphyses at 2 weeks
(Fig. 2A). Consistent with this, the number of osteoclasts formed
in bone marrow cultures from Dmp1 KO mice in the presence of
1,25(OH)2D3 was less than 50% of that in control (Fig. 2B, left bar).
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normally when provided with the necessary factors RANKL and
M-CSF because the number of osteoclasts formed by Dmp1 KO
spleen cells (osteoclast progenitors) is identical to that of control
spleen cells (Fig. 2B, right bar). Yet resorption lacunae or pit
formation ondentin, an assay fortesting osteoclast function, was
equivalent for both the Dmp1 KO mice and the controls (Fig. 2B,
right panel),suggesting that the Dmp1 KO precursors and mature
osteoclasts are normal. Together, these data suggest that the
abnormalitiesinremodelinginDmp1KOmicearerelatedtoboth
the altered osteoblast function and the reduction of the number
of osteoclasts. The osteoclast defect appears to reside in cells of
Fig. 2. Reductions of osteoclasts in Dmp1 null mice. (A) TRAP stained 3-
week-old femurs showed a sharp reduction in osteoclast number (data
are mean SEM from n¼4 to 6 animals).
  p<.01 using Student’s t test.
(B) Bone marrow, a source of both osteoclast precursors and their
supporting cells, from Dmp1 KO mice only generated half the number
of osteoclasts as that from control mice. However, when stimulated with
RANKL and M-CSF, spleen, as a source of osteoclast precursors, from the
Dmp1 KO mice generated equivalent numbers of osteoclasts and pit
formation on dentin as spleen from the control mice (data are mean
 SEM from n¼4 to 6 animals/3 replicates).
 p<.05 using Student’s
t test. (C) Real-time PCR analysis showed that Dmp1 KO long bones
express less RANKL but three times more OPG, with a ratio of RANKL to
OPG of 1:5 than in the control (data are mean SEM from 3 replicates).
 p<.05;
  p<.01, using Student’s t test.
Fig. 1. Abnormal bone remodeling in the Dmp1 null mouse (Dmp1 KO,
rightpanels),whichis exacerbatedwithage.(A)Photographs of3-day-old
forelimbs stained with alizarin red/alcian blue showing that the KO
cartilage is remodeled less than control. (B) Radiographs of 3-day-old
hind limbs of Dmp1 control and KO images showing more trabecular
bone in the KO bone marrow, which is further confirmed by ALP enzyme
activity andvonKossa staining.(C, D) Photographs of alizarinred–stained
femur (day 17), craniofacial bones (1 year), mandibular bone, and femur
(1 year, X-ray) display severe defects of bone remodeling with age.
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rather than an intrinsic defect in the osteoclasts themselves
(Fig. 2B). In search of the mechanism by which the number of
Dmp1 KO osteoclasts is reduced, we performed both RT-PCR
(Supplemental Fig. S2) and qPCR (Fig. 2C) analyses using long
bone samples with the bone marrow preserved and showed
that the Dmp1 KO long bone expressed less RANKL and three
times more OPG with a 1:5 ratio of RANKL to OPG than the
control (Fig. 2C).
Roles of phosphorus in the formation of secondary
ossification centers
The Dmp1 KO phenotype is associated with hypophosphatemia
and elevated FGF-23 concentrations. One or both of these may
be critical mediators of the skeletal defects. In support of this
hypothesis, we have shown previously that a high-phosphate
diet significantly improves bone mineralization in the Dmp1 KO
tibia.
(1) In addition, the high-phosphate diet also restored the
defectsinthegrowthplateofDmp1KOmice.
(1)Nevertheless, the
high-phosphate diet only partially rescued the osteomalacia
phenotype in Dmp1 KO mice.
(1) This is likely due to the fact that
the Dmp1 KO phenotype begins postnatally,
(18) but the
correction of phosphate homeostasis by the high-phosphate
diet was started at week 3 after weaning.
(1) To overcome this
limitation and to avoid the potential influence of circulating
factors, such as parathyroid hormone (PTH), 1,25(OH)2D3, and
FGF-23, ex vivo experiments were performed in which the
phosphate levels could be controlled experimentally using a
metatarsal organ culture system. In this experiment, we showed
a dose-dependent correlation between increasing phosphate
and the formation of secondary epiphyseal ossification in 8-day-
old metatarsals cultured for 8 days in both the control and Dmp1
KO pups (Fig. 3A, mCT images; Fig. 3B, alizarin red stain,
photographic images of metatarsals). Furthermore, we showed
that the expression level of DMP1 in the wild-type metatarsal
culture was positively correlated with the BGP level (Fig. 3C).
Interestingly, we also demonstrated a dose-dependent correla-
tion between the increasing phosphate and the formation of
mineralized nodule in the calvarial cell isolated from both the
control and the Dmp1 KO pups (Fig. 3D). These data suggest that
the delayed formation of secondary ossification centers is mainly
due to the hypophosphatemia.
Pathogenic roles of FGF-23 in Dmp1-KO mice
Having established that phosphate levels are key for manifesta-
tionofthe Dmp1KO phenotype, we nextdetermined the relative
role of elevated FGF-23, a potent phosphaturic hormone that
promotes renal phosphate excretion.
(11,12,29) To test whether
restorationofDmp1KOphosphatehomeostasiscould rescuethe
Dmp1KOphenotype,weinjectedneutralizingantibodiesagainst
FGF-23
(20) into Dmp1 KO mice.
The Dmp1 KO mice showed delayed formation of secondary
ossification centers, as demonstrated by radiography (Fig. 4A),
which was used as a readout for testing the role of Pi in Dmp1 KO
mice. As expected, injections of FGF-23 antibodies restored
serum phosphate levels (Fig. 4B). We then showed the rescue of
secondary ossification defects in vertebrae (Fig. 4C) and femoral
bone (Fig. 4D), as determined by mCT analysis. Quantitation
confirmed that the BV/TV% in Dmp1 KO mice was restored to the
control level by 28 days after injections of FGF-23 antibodies. We
also showed a full rescue of the growth plate (Fig. 4E), which is in
agreement with the high-Pi diet rescue.
(1)
Histologic analyses using toluidine blue staining (an assay
revealing bone marrow cells and blood vessels; Fig. 5A), ALP (an
early marker for bone formation; Fig. 5B), and E11 (a marker for
newly formed osteocytes; Fig. 5C) showed that there was
delayed blood vessel formation and bone marrow formation in
Dmp1 KO mice and that the injections of FGF-23 antibodies
rescued these abnormalities.
Treatment with FGF-23 antibodies also improved the
abnormalities in cortical bone observed in Dmp1 KO mice, as
shown in Fig. 6. Note that with FGF-23 antibody treatments, the
Fig. 3. Ex vivo secondary ossification in metatarsals is phosphate dose
dependent in both Dmp1 control and KO osteoblasts. (A) Representative
mCT images of 8-day-old mouse metatarsal organ cultures showing that
ex vivo formation of both Dmp1 control and KO epiphyses is (-glycer-
ophosphate (BGP) dose dependent. (B) Representative alizarin red–
stained images of 8-day-old mouse metatarsal organ cultures showing
that theex vivoformation of bothDmp1control andKO epiphysesis BGP
dose dependent. (C) The DMP1 expression pattern appears to be BGP
dose dependent in the cultured wild-type metatarsal. (D) Alizarin red–
stained images of newborn mouse calvarial cultures showing that the
mineralized nodule formation is BGP dose dependent in both Dmp1
control and KO cultures.
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KO mice (and other models of osteomalacia) is restored to a
pattern resembling that in control mice, with discrete lines of
calcein and alizarin red labeling, suggesting a more normal
bone-formation rate (Fig. 6A). Bone quality, osteocyte morphol-
ogy, and osteoclast number also were partially improved, as
shown by less cortical porosity (Fig. 6B), reduced amounts of
osteoid (Fig. 6C), improved osteocyte surface (Fig. 6D), and an
increase in osteoclasts in the trabecular region (Fig. 6E).
Histologic analyses showed that FGF-23 antibody treatments
also partially reversed the increase in osterix, Col1a1, and FGF-23
expression normally seen in Dmp1 KO mice (Fig. 7A–C) and
restored expression of sclerostin, a marker of mature osteocytes
that is largely undetectable in Dmp1 KO osteocytes (Fig. 7D).
These data suggest that FGF-23 antibodies can rescue the defect
in osteocyte maturation in Dmp1 KO mice. This is likely mediated
through the effects of the neutralizing antibody to restore
phosphate levels (Fig. 4B).
Discussion
We previously showed that DMP1 and phosphate homeostasis
are critical for bone and tooth formation using a Dmp1 null
animal model, that is, a hypophosphatemic rickets/osteomalacia
model.
(1,18,30) However, how phosphate homeostasis and DMP1
contribute to the mineralization remains unclear. In this study,
we used the ex vivo culture of metatarsal organs, the primary
calvarial cell culture, and application of neutralizing FGF-23
antibodies to investigate the specific roles of Pi and DMP1 in
bone biology during postnatal development. Our key findings
are (1) that Dmp1 null mice develop defective bone remodeling
owing to abnormal osteoblast formation and (2) that restoration
of Pi homeostasis in Dmp1 null mice via injections of anti-FGF-23
antibodies i.p. fully rescue defects in the growth plate and the
secondary ossification process.
Dmp1 null mice develop severe skeletal abnormalities with
age, suggesting a defect in the bone-remodeling process, which
normally is carried out by osteoblasts, which form bone, and
osteoclasts, which resorb bone. Indeed, our previous study
(1) and
the current study have shown that the Dmp1 null osteoblasts
have altered functions. They continuously express many
osteoblast-specific genes, such as osterix, Col1a1, osteocalcin,
FGF-23, and E11, and fail to differentiate into mature osteocytes.
This defect in osteoblast differentiation apparently is caused by
hypophosphatemia because the isolated calvarial osteoblasts
mineralize normally ex vivo if sufficient phosphate is provided
(Fig. 3D). Furthermore, we have shown that the Dmp1 null bone
displays a reduced number of osteoclasts. This reduction in
osteoclast formation is secondary to the defects in cells of the
stromal/osteoblast lineage because these null cells express a
reduced ratio of RANK/OPG in Dmp1 null bone. This pathologic
change could be caused by both the intrinsic osteoblast defect
owing to a loss of DMP1 and an indirect role of hypopho-
sphatemia on Dmp1 null osteoblasts because restoration of Pi by
injections of Fgf23Ab greatly improves osteoclast numbers and
bone remodeling (Fig. 6E). However, we cannot rule out the
possibility that hypophosphatemia also may adversely affect
osteoclast formation and function directly in vivo.
PTH normally plays an important role in the regulation of
osteoclastogenesis: A continuous high level of PTH stimulates
this process, whereas a sustained low level inhibits osteoclast
formation.
(29) The best example is primary hyperparathyroidism,
where a high level of PTH leads to an increase in osteoclast
activity and bone loss. Interestingly, the PTH level in the Dmp1
null mouse is constantly higher (5 to 10 times) than that in age-
matched control animals,
(1) but the osteoclast number is less
than 50% of that in controls (Fig. 2). Apparently, the defect in
osteoclastogenesis observed in Dmp1 null mice cannot be
explained by the physiologic catabolic role of PTH. On the other
Fig. 4. Rescue of Dmp1 KO phosphate homeostasis and secondary
ossification using anti-FGF-23 antibody injections. (A) Representative
X-ray images of Dmp1 KO long bones showed the delayed secondary
ossification (epiphyses formation) and expanded metaphyses (day 14).
(B) Injections of FGF-23 Abs in the control and KO mice for 9 days starting
from day 6 significantly increased the serum Pi level in control mice and
restored Pi levels to control levels in Dmp1 KO mice with little effect
on serum Ca levels (lower panel) (data are mean SEM from n¼4t o
6 animals).
 p<.05;
   p<.01 compared with PBS using Student’s t test.
(C, D) mCT data showed partial (for 9-day injections) or full (for 22-day
injections) rescue of epiphyses formation in the KO vertebrae (C) and
femurs (D) (data are mean SEM from n¼4 to 6 animals).
 p<.05;
  p<.01comparedwithcontrol.(E)Safranin-Odatashowedfullrescueof
growth plate formation in the KO tibias.
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trabecular bone accumulation in the entire bone marrow plus a
lack of tooth eruption. But none of these changes is observed in
this animal model except for an expanded metaphysis. Does this
mean that the number of osteoclasts would be even lower if the
PTH factor were removed from the Dmp1 null mice or that PTH
has little effect on the defects in Dmp1 null bone remodeling?
Our future study seeks to understand the role of PTH in this
animal model.
FGF-23 has been shown to be a potent phosphaturic hormone
that promotes renal phosphate excretion,
(11,12,29) and it is
dramatically elevated in Dmp1 null mice.
(1) However, its
pathogenic role has not been completely established owing
to the fact that Dmp1 null mice exhibit the phenotype of Fgf23
null mice.
(31) In this study, we applied neutralizing antibodies
against FGF-23
(20) into Dmp1 null mice. We clearly showed that
FGF-23 antibodies restored serum phosphate level and rescued
the defects in the secondary ossification center in both long
bone and vertebrae. The ex vivo metatarsal assay showed that
the formation of secondary ossification was phosphate dose–
dependent, and there was no difference between the control
and Dmp1 null metatarsals, suggesting that rescue of the
secondary ossification center by FGF-23 antibodies likely was
due to the restoration of phosphate homeostasis. However, this
does not necessarily mean that the Pi is the only factor required
for secondary ossification. It is known that FGF-23 targets
primarily in the kidney to induce urinary phosphate excretion
and suppress 1,25(OH)2D3 synthesis.
(32,33) FGF-23 also acts
Fig. 5. Rescue of the delay in marrow cavity formation in Dmp1 KO mice by injections of FGF-23 antibodies (control, left panels; KO, middle panels; and
KOþAb injection, right panels) Injections of FGF-23 Abs accelerated bone marrow formation in the KO femur epiphyses,as documented by toluidine blue
staining(A,showingadelayinformationofbloodvesselsandlackofbonemarrow),ALPimmunohistochemistrystaining(B,signalinred,showingresidual
ALP stained trabecular bone in the center of the epiphyses and lack of formation of a marrow cavity), and E11 immunostain (C, signal in brown, showing
the E11-stained trabecular bone in the center of the epiphyses and lack of formation of a marrow cavity).
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secretion.
(34) Ironically, neither 1,25(OH)2D3 nor PTH seems
to play an apparent role in the Dmp1 null phenotype owing
to the following two facts: (1) The serum level of 1,25(OH)2D3
is only slightly lower in Dmp1 null mice, and (2) the PTH level
in Dmp1 null mice is 5 to 10 times higher than in the control
mice.
(1)
Interestingly, we noticed that in the long bone, the restoration
of phosphate homeostasis by FGF-23 antibodies only partially
rescued the bone-formation rate and osteomalacia, suggesting
that DMP1 also plays a direct role in mineralization.
Fig. 7. Rescue of molecular markers in the Dmp1 KO osteoblast (Ob) and
osteocyte (Oyc) by injections of FGF-23 antibodies (control, left panels;
KO, middle panels; and KOþAb injection, right panels). (A) Immunohis-
tochemistry assay showed an increase in osterix expression in Dmp1 null
osteocytes and a return to the control level in the KO osteocytes injected
with FGF-23 Ab. In situ hybridization shows a decrease in Col1a1 mRNA
(B,signalinred)andFgf23mRNA(C,signalinred)inDmp1KOosteoblasts
and osteocytes injected with FGF-23 Ab. Immunohistochemical staining
for sclerostin showed a reduction in osteocytes from Dmp1 KO animals
compared with control, which is restored in osteocytes from animals
injected with FGF-23 Ab (D).
Fig. 6. Partial rescue of the malformed long bone in Dmp1 KO mice by
injections of Anti-FGF-23 Ab (control, left panels; KO, middle panels; and
KOþAb injection, right panels). (A) Confocal microscope images of
fluorochrome labeling counterstained with DAPI in 7-week-old mouse
tibias (red¼alizarinred; green¼calcein;blue¼DAPI).Note that the high-
Pi diet restored the bone-formation labeling pattern in KO tibias to a
patternresemblingcontrol;however,thelabelisstillthickerinwidththan
thecontrol.(B) Representative mCTimagesshowimprovement ofcortical
bone formation by injection of FGF-23 Ab at days 15 and 28 because the
bone is less porous. (C) Goldner’s staining shows a minor reduction in the
amount of osteoid in KO cortical bone that received FGF-23 antibodies.
(D) Backscattered SEM displayed a partial restoration of osteocyte
morphology, although the mineralization was largely unchanged (the
mineral content is shown in white). (E) Representative TRAP-stained
femur sections showed that Dmp1 null osteoclasts were distributed
mainly on the metaphysis surface, and there were few trabeculae (middle
panel). In contrast, there were more TRAP
þ cells plus more trabeculae
formed in the FGF-23-injected metaphysis, suggesting a partial rescue in
osteoclastogenesis (right panel).
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proteinexpressionsandmetabolicactivityduringthematuration
ofosteoblasts intoosteocytes.This processisrathercomplexand
largely unknown owing to technique difficulties that mature
osteocytes reside in the mineralized matrix and that it is hard to
isolate and study them in an in vitro condition created similar to
their in vivo environment. However, our current studies suggest
that DMP1 and phosphate homeostasis are likely the key factors
in control of this downsizing process because there were
abnormal increases in many osteoblast-specific proteins in the
Dmp1 KO osteocytes that are restored when phosphate home-
ostasis is normalized by neutralizing antibodies against FGF-23.
Thesefindings were incorporated into a model, as shown inFig.8.
However, this model, which provides a powerful framework
for future studies in osteocyte maturation and mineralization,
has certain limitations. For example, markers for early versus
more mature osteocytes are not well characterized, and the
morphologic characteristics of early versus mature osteocytes
are still largely unknown. Second, the critical role of Pi in
mineralization should not be purely limited to Pi itself because
several reports demonstrated the importance of the ratio of
Pi/PPi (inorganic pyrophosphate) on mineralization.
(35–37) These
studies showed that PPi, produced by the nucleoside tripho-
sphate pyrophosphohydrolase, inhibits the formation and
growth of hydroxyapatite crystals in mineralization. Non-
tissue-specific alkaline phosphatase (TNAP) and Enpp1 are two
key regulators of the extracellular PPi concentrations required for
controlled bone mineralization of PPi.
In conclusion, our current findings suggest that osteocytes not
only control their own differentiation and mineralization but also
may couple osteoclast formation, growth plate development,
and the formation of secondary ossification centers through
maintaining phosphate homeostasis via tightly controlled FGF-
23 expression. FGF-23 antibodies may be developed for clinical
treatment of hypophosphatemic disorders in the future.
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